Clinical Trials Browser

Biliary Tract Neoplasms

Brain Neoplasms

Colorectal Neoplasms

Lung Diseases, Interstitial

Rectal Neoplasms Malignant

Colorectal Neoplasms

Medulloblastoma

Colorectal Neoplasms

Ovarian Neoplasms, Recurrence

Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Appendiceal Neoplasms, Colorectal Neoplasms

Lung Neoplasms

Colonic Neoplasms

Colorectal Neoplasms

Ovarian Neoplasms

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Colorectal Neoplasms

Advanced Ovarian Cancer

Extensive Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Neutropenia, Colorectal Neoplasms

Stomach Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Colorectal Neoplasms

Ovarian Neoplasms

Colorectal Neoplasms

Rectal Neoplasms

Colorectal Neoplasms

Spinocerebellar Degenerations, Colorectal Neoplasms

Colorectal Cancer Metastatic

Ovarian Neoplasms

Unresectable Metastatic Colorectal Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Neoplastic Cells, Circulating

Colorectal Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Carcinoma, Hepatocellular

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Clinical Trials

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

COLIBRI-GI

PNOC044

ARIEL-ENGIC

TROY

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

REFISH

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

ANGELICA

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

QL1706

IMMUNOLIFE2

BETWEEN

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer

Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study

SCRIPBOT

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

NEOCATS

PHARBEVACOL

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma

A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab